Physician profile
Robert B Rutherford
NPI 1427461755
$9,502.51
in general payments reported to CMS, 2019-2025
46 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,307 · 2022: $3,784 · 2023: $1,654 · 2024: $1,339 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.49 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,645.38 | 2022 | |
| Novo Nordisk INC | $1,435.87 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,123.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $587.68 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $390.76 | 2022-2025 | Auvelity |
| Glaxosmithkline, LLC. | $379.31 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $353.20 | 2023-2025 | Azstarys |
| Lilly USA, LLC | $252.24 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $245.35 | 2021-2024 | |
| Lundbeck LLC | $203.53 | 2021-2025 | Vyepti |
| Idorsia Pharmaceuticals US INC | $174.65 | 2023 | Quviviq |
| Astellas Pharma US INC | $168.07 | 2023-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $108.66 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.31 | 2021-2025 | Xifaxan |
| Daiichi Sankyo INC. | $92.16 | 2022-2025 | Injectafer |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rutherford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.